Dr. Nicholas Hoffman

Dr. Nicholas Hoffman has a diverse work experience spanning multiple industries and roles. Dr. Nicholas served as the Chief Executive Officer at Paladin LLC since April 2016 and as the Chairperson of the Board at MitoGrade Pharmaceuticals since April 2015. In addition, they worked at the University of Nebraska Medical Center from September 2015 to September 2016, where they managed and designed a clinical cardiovascular research program. Dr. Hoffman also held the position of Chief Investment Officer at Sandhills Capital Management, LLC from November 2012 to April 2016. Prior to that, they served as a Partner at Bond Capital Income Fund II since November 2012. Earlier in their career, Dr. Hoffman worked as a Postdoctoral Research Fellow at Temple University from August 2014 to September 2015, focusing on translational research for cardiovascular diseases. Overall, they have shown a strong commitment to research, education, and leadership in their various roles.

Dr. Nicholas Hoffman's education history includes a Bachelor's Degree in Biology, General from the University of Nebraska at Omaha, which they obtained between 2001 and 2006. Dr. Nicholas then pursued a Doctor of Philosophy (Ph.D.) in Biochemistry at Temple University - Lewis Katz School of Medicine from 2010 to 2014. Additionally, they hold a Master of Business Administration (MBA) degree in Accounting from the University of Nebraska at Omaha. Furthermore, Dr. Hoffman has obtained a Class A License, Commercial Unlimited in Nebraska and Iowa from the International Code Council. The specific dates for the certification and MBA degree were not provided.